AN2 Therapeutics, Inc.
No enriched coverage for $ANTX in the last 7 days.
No SEC Form 4 filings for $ANTX in the last 30 days.
See all $ANTX insider activity →AN2 Therapeutics, Inc. (ANTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001880438 0001880438 2026-06-03 2026-06-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03,
Williams Sarah Joanne (Principal Accounting Officer) sold 265 shares of AN2 Therapeutics, Inc. (ANTX) at $4.43 on 2026-05-29.
AN2 Therapeutics (ANTX) has established a new $80 million at-the-market (ATM) stock sale program with Jefferies to issue common stock. This move replaces a previous ATM agreement with TD Securities, under which the company had raised approximately $20 million. The company's stock currently holds a Hold rating with a $3.50 price target from analysts, while TipRanks' AI Analyst Spark rates ANTX as Neutral due to weak financial performance despite positive technicals.
Recent ANTX coverage spans financial news, corporate actions and insider activity.
Routine corporate governance vote results; limited direct fundamental change, but can affect near-term sentiment around board/audit continuity.
Insider open-market sale is a modest negative signal, but size is small and lacks a new fundamental catalyst.
The announcement of an additional $80 million ATM program indicates increased capital raising capacity, potentially diluting existing shares but also providing funds for growth. Current analyst ratings suggest a cautious outlook with a Hold rating and a $3.50 price target. TipRanks' AI Analyst rates the stock as Neutral due to weak financial performance despite positive technicals.
The $40 million private placement financing signals strong investor confidence in AN2 Therapeutics' pipeline and strategic direction, potentially leading to positive stock performance.
Leadership changes and salary adjustments at AN2 Therapeutics may signal internal restructuring, potentially affecting investor confidence and stock performance.
alphai scores every news story that mentions ANTX with an AI model for sentiment and relevance, and aggregates insider trades from AN2 Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AN2 Therapeutics, Inc. (ANTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001880438 0001880438 2026-06-03 2026-06-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03,
3 min readWilliams Sarah Joanne (Principal Accounting Officer) sold 265 shares of AN2 Therapeutics, Inc. (ANTX) at $4.43 on 2026-05-29.
1 min readAN2 Therapeutics (ANTX) has established a new $80 million at-the-market (ATM) stock sale program with Jefferies to issue common stock. This move replaces a previous ATM agreement with TD Securities, under which the company had raised approximately $20 million. The company's stock currently holds a Hold rating with a $3.50 price target from analysts, while TipRanks' AI Analyst Spark rates ANTX as Neutral due to weak financial performance despite positive technicals.
2 min readAN2 Therapeutics, a clinical-stage biopharmaceutical company, announced a private placement financing expected to generate approximately $40 million in gross proceeds. The financing includes the sale of common stock and pre-funded warrants to new and existing institutional investors, including Coastlands Capital, Commodore Capital, and Vivo Capital. The proceeds will support the company's development of novel small molecule therapeutics utilizing its boron chemistry platform.
4 min readAN2 Therapeutics (ANTX) has appointed Sarah Williams as Principal Accounting Officer with an increased salary, effective February 1, 2026. Simultaneously, CFO Lucy Day's salary will be reduced as part of the company's cost-saving efforts, while her other employment terms remain largely unchanged. The company's stock currently holds a "Hold" rating with a $1.00 price target based on analyst forecasts.
3 min read
